高级检索
当前位置: 首页 > 详情页

TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Cent Hosp Jingzhou, Dept Orthoped, Jinzhou 434100, Hubei, Peoples R China [2]Shanghai Changzheng Hosp, Dept Med Oncol, Shanghai 200070, Peoples R China [3]Xin Xiang Med Univ, Affiliated Hosp 1, Weihui 453100, Henan, Peoples R China [4]Orthopaed Hosp Nanyang, Dept Orthoped, Nanyang 473003, Henan, Peoples R China [5]Shanghai Hengrui Pharmaceut Co, Shanghai 20035, Peoples R China [6]Shanghai Xuhai Biol Technol Co Ltd, Shanghai 20032, Peoples R China [7]Northeast Agr Univ, Coll Life Sci, Dept Pharmaceut Biotechnol, Harbin 150030, Heilongjiang, Peoples R China [8]Shanghai Tongren Hosp Changning, Dept Surg, Shanghai 200050, Peoples R China
出处:
ISSN:

关键词: TET1 HDAC inhibitor TSA breast cancer

摘要:
Histone deacetylases (HDACs) are important in chromatin remodeling and epigenetic regulation of gene expression. Histone deacetylase inhibitors (HDACi) have highly effective anti-metastatic and anti-angiogenic activity in various types of cancer, while the molecular mechanisms involved in this process are not fully understood. In the present study, trichostatin A (TSA), a HDACi, was found to suppress MCF-7 breast carcinoma cell invasion and upregulate TET1 expression in a dose-dependent manner. TET1, a dioxygenase involved in cytosine demethylation, is downregulated during breast cancer progression. TET1 knockdown in MCF-7 cells facilitates cell invasion, inhibits the expression of tissue inhibitors of metalloproteinase 2/3 (TIMP2/3) and promotes matrix metalloproteinases (MMP) 2/9 transcriptional activity. Importantly, TET1 depletion impaired the inhibitory effect of TSA on breast cancer cell invasion. Together, these results illustrated a mechanism by which TET1 partially mediates HDACi elicited suppression of breast cancer invasion.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2012]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者机构: [1]Cent Hosp Jingzhou, Dept Orthoped, Jinzhou 434100, Hubei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [8]Shanghai Tongren Hosp Changning, Dept Surg, Shanghai 200050, Peoples R China [*1]Department of Surgery, Shanghai Tongren Hospital of Changning, 768 Yuyuan Road, Shanghai 200050, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)